In the current work, we have described a method allowing recovery of BC CTCs with different EMT phenotypes using a mixture of epithelial (EpCAM, ECAD) and mesenchymal (csVIM, MCAM) markers analyzed by immunofluorescence that could be further transcriptomically characterized. The gene discussed is EPCAM; the disease is breast cancer.